Last reviewed · How we verify
Mesalazine plus Lactobacillus casei
Mesalazine reduces intestinal inflammation while Lactobacillus casei provides beneficial bacteria to restore and maintain a healthy gut microbiome.
Mesalazine reduces intestinal inflammation while Lactobacillus casei provides beneficial bacteria to restore and maintain a healthy gut microbiome. Used for Inflammatory bowel disease (ulcerative colitis and Crohn's disease), Maintenance of remission in inflammatory bowel disease.
At a glance
| Generic name | Mesalazine plus Lactobacillus casei |
|---|---|
| Sponsor | Hospital Cristo Re |
| Drug class | Anti-inflammatory agent plus probiotic combination |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
Mesalazine (5-aminosalicylic acid) acts as a topical anti-inflammatory agent in the colon, inhibiting prostaglandin and leukotriene production to reduce mucosal inflammation. Lactobacillus casei is a probiotic that colonizes the intestinal tract, competing with pathogenic bacteria, strengthening the intestinal barrier, and modulating local immune responses to promote a balanced microbiota.
Approved indications
- Inflammatory bowel disease (ulcerative colitis and Crohn's disease)
- Maintenance of remission in inflammatory bowel disease
Common side effects
- Abdominal pain
- Diarrhea
- Nausea
- Headache
- Rash
Key clinical trials
- Microbiota and Probiotic Therapy in Ulcerative Colitis Patients
- Mesalazine and/or Lactobacillus Casei in the Diverticular Disease of the Colon (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mesalazine plus Lactobacillus casei CI brief — competitive landscape report
- Mesalazine plus Lactobacillus casei updates RSS · CI watch RSS
- Hospital Cristo Re portfolio CI